Aquatic photochemistry, abiotic and aerobic biodegradability of thalidomide: Identification of stable transformation products by LC-UV-MSn

Science of the Total Environment

Volumn 463-464, Issue , 2013, Pages 140-150

  Mahmoud, Waleed M M ^a,b   Trautwein, Christoph ^a   Leder, Christoph ^a   Kümmerer, Klaus ^a  

^a LEUPHANA UNIVERSITY OF LÜNEBURG   (Germany)

^b Suez Canal University   (Egypt)

Author keywords

Aquatic environment; Biodegradation; Dead end transformation product; Pharmaceuticals; Photodegradation; QSAR

Indexed keywords

ANTI-INFLAMMATORY ACTIVITY; AQUATIC ENVIRONMENTS; ENVIRONMENTAL RISK ASSESSMENT; PHARMACOLOGICAL ACTIVITY; PHOTOLYTIC TRANSFORMATION; QSAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS; TRANSFORMATION PRODUCTS;

BOTTLES; COMPUTATIONAL CHEMISTRY; DISEASES; DRUG PRODUCTS; ELECTRIC LAMPS; ISOMERS; LIGHT SOURCES; MICROBIOLOGY; MOLECULAR GRAPHICS; PHOTODEGRADATION; PHOTOLYSIS; RISK ASSESSMENT;

BIODEGRADATION;

ORGANIC CARBON; THALIDOMIDE;

AQUATIC ENVIRONMENT; BIODEGRADATION; COMPUTER SIMULATION; DISSOLVED ORGANIC CARBON; DRUG; EXPERIMENTAL STUDY; MODELING; PHOTOCHEMISTRY; RISK ASSESSMENT; SOFTWARE;

AQUATIC ENVIRONMENT; AQUATIC PHOTOCHEMISTRY; ARTICLE; BIODEGRADABILITY; BIODEGRADATION; COMPUTER ANALYSIS; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG DEGRADATION; ENVIRONMENTAL RISK ASSESSMENT; ISOMER; LIGHT; LIQUID CHROMATOGRAPHY; MOLECULAR WEIGHT; PHOTOCHEMISTRY; PHOTOLYSIS; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RISK ASSESSMENT; ULTRAVIOLET SPECTROSCOPY; WATER POLLUTION;

AQUATIC ENVIRONMENT; BIODEGRADATION; DEAD-END TRANSFORMATION PRODUCT; PHARMACEUTICALS; PHOTODEGRADATION; QSAR;

AEROBIOSIS; BIODEGRADATION, ENVIRONMENTAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; MASS SPECTROMETRY; PHOTOLYSIS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; THALIDOMIDE; ULTRAVIOLET RAYS; WATER;

EID: 84879488074     PISSN: 00489697     EISSN: 18791026     Source Type: Journal    
DOI: 10.1016/j.scitotenv.2013.05.082     Document Type: Article

References (52)

1. Bosch M.E., Sánchez A.R., Rojas F.S., Ojeda C.B. Recent advances in analytical determination of thalidomide and its metabolites. J Pharm Biomed 2008, 46:9-17.
2. Canonica S., Meunier L., von Gunten U. Phototransformation of selected pharmaceuticals during UV treatment of drinking water. Water Res 2008, 42:121-128.
3. Carballa M., Omil F., Lema J.M., Llompart M., García-Jares C., Rodríguez I., et al. Behavior of pharmaceuticals, cosmetics and hormones in a sewage treatment plant. Water Res 2004, 38:2918-2926.
4. Chakravarti S.K., Saiakhov R.D., Klopman G. Optimizing predictive performance of CASE Ultra expert system models using the applicability domains of individual toxicity alerts. J Chem Inf Model 2012, 52:2609-2618.
5. Eriksson T., Björkman S., Roth B., Björk H., Höglund P. Drug metabolism: hydroxylated metabolites of thalidomide: formation in-vitro and in-vivo in man. J Pharm Pharmacol 1998, 50:1409-1416.
6. European Commission Technical guidance document on risk assessment part II http://ec.europa.eu/environment/chemicals/exist_subst/pdf/tgdpart2_2ed.pdf.
7. Fatta-Kassinos D., Vasquez M.I., Kümmerer K. Transformation products of pharmaceuticals in surface waters and wastewater formed during photolysis and advanced oxidation processes - degradation, elucidation of byproducts and assessment of their biological potency. Chemosphere 2011, 85:693-709.
8. Friedrich J., Längin A., Kümmerer K. Comparison of an electrochemical and luminescence-based oxygen measuring system for use in the Closed Bottle test. Clean - Soil Air Water 2013, 41:251-257.
9. Gartiser S., Urich E., Alexy R., Kümmerer K. Ultimate biodegradation and elimination of antibiotics in inherent tests. Chemosphere 2007, 67:604-613.
10. Gros M., Petrović M., Barceló D. Multi-residue analytical methods using LC-tandem MS for the determination of pharmaceuticals in environmental and wastewater samples: a review. Anal Bioanal Chem 2006, 386:941-952.
11. Halling-Sørensen B., Nors Nielsen S., Lanzky P.F., Ingerslev F., Holten Lützhøft H.C., Jørgensen S.E. Occurrence, fate and effects of pharmaceutical substances in the environment - a review. Chemosphere 1998, 36:357-393.
12. Heberer T. Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of recent research data. Toxicol Lett 2002, 131:5-17.
13. Howard P.H., Muir D.C.G. Identifying new persistent and bioaccumulative organics among chemicals in commerce II: pharmaceuticals. Environ Sci Technol 2011, 45:6938-6946.
14. ISO (International Standards Organization) Water quality - determination of dissolved oxygen. German standard methods for the examination of water, wastewater and sludge 1990, WILEY-VCH Verlag GmbH & Co. KGaA; Weinheim, and Beuth Verlag GmbH, Berlin.
15. Johnson A.C., Jürgens M.D., Williams R.J., Kümmerer K., Kortenkamp A., Sumpter J.P. Do cytotoxic chemotherapy drugs discharged into rivers pose a risk to the environment and human health? An overview and UK case study. J Hydrol 2008, 348:167-175.
16. Kang S.J., Allbaugh T.A., Reynhout J.W., Erickson T.L., Olmstead K.P., Thomas L., et al. Selection of an ultraviolet disinfection system for a municipal wastewater treatment plant. Water Sci Technol 2004, 50:163-169.
17. Khaleel N.D.H., Mahmoud W.M.M., Hadad G.M., Abdel-Salam R.A., Kümmerer K. Photolysis of sulfamethoxypyridazine in various aqueous media: aerobic biodegradation and identification of photoproducts by LC-UV-MS/MS. J Hazard Mater 2013, 244-245:654-661.
18. Klán P., Wirz J. Photochemistry of organic compounds: from concepts to practice 2009, Wiley, Chichester, U.K.
19. Kosjek T., Heath E. Occurrence, fate and determination of cytostatic pharmaceuticals in the environment: biogenic volatile organic compounds S.I. TrAC Trends Anal Chem 2011, 30:1065-1087.
20. Pharmaceuticals in the environment: sources, fate, effects and risks 2008, Springer, Berlin, Heidelberg. 3rd ed. K. Kümmerer (Ed.).
21. Kümmerer K. The presence of pharmaceuticals in the environment due to human use - present knowledge and future challenges. J Environ Manage 2009, 90:2354-2366.
22. Kümmerer K., Al-Ahmad A. Estimation of the cancer risk to humans resulting from the presence of cyclophosphamide and ifosfamide in surface water. Environ Sci Pollut Res 2010, 17:486-496.
23. Kümmerer K., Al-Ahmad A., Steger-Hartmann Thomas Epirubicin hydrochloride in the aquatic environment - biodegradation and bacterial toxicity. Umweltmed Forsch Prax 1996, 1:133-137.
24. Laboratory of Mathematical Chemistry "Prof. Dr. Assen Zlatarov" University, Bourgas, Bulgaria. Oasis Catalogic software V.5.11.6TB 2012.
25. Lam M.W., Mabury S.A. Photodegradation of the pharmaceuticals atorvastatin, carbamazepine, levofloxacin, and sulfamethoxazole in natural waters. Aquat Sci 2005, 67:177-188.
26. Liberti L., Notarnicola M. Advanced treatment and disinfection for municipal wastewater reuse in agriculture. Water Sci Technol 1999, 40:235-245.
27. n. Chemosphere 2012, 88:1170-1177.
28. Meise W., Ockenfels H., Köhler F. Teratologische Prüfung der Hydrolysenprodukte des Thalidomids. Experientia 1973, 29:423-424.
29. Meneses M., Pasqualino J.C., Castells F. Environmental assessment of urban wastewater reuse: treatment alternatives and applications. Chemosphere 2010, 81:266-272.
30. Meyring M., Strickmann D., Chankvetadze B., Blaschke G., Desiderio C., Fanali S. Investigation of the in vitro biotransformation of R-(+)-thalidomide by HPLC, nano-HPLC, CEC and HPLC-APCI-MS. J Chromatogr B 1999, 723:255-264.
31. Nikolaou A., Meric S., Fatta D. Occurrence patterns of pharmaceuticals in water and wastewater environments. Anal Bioanal Chem 2007, 387:1225-1234.
32. Oosterhuis M., Sacher F., ter Laak T.L. Prediction of concentration levels of metformin and other high consumption pharmaceuticals in wastewater and regional surface water based on sales data. Sci Total Environ 2013, 442:380-388.
33. Organisation for Economic Co-operation and Development OECD guidelines for the testing of chemicals degradation and accumulation test no. 302C: inherent biodegradability: modified MITI test (II) 1981, OECD Publishing, Paris.
34. Organisation for Economic Co-operation and Development OECD guideline for testing of chemicals 301D: ready biodegradability. Closed Bottle test 1992, OECD Publishing, Paris.
35. Organisation for Economic Co-operation and Development OECD guideline for testing of chemicals 301F: ready biodegradability. manometric respiratory test 1992, OECD Publishing, Paris.
36. Petrovic M., Barceló D. LC-MS for identifying photodegradation products of pharmaceuticals in the environment: pharmaceutical-residue analysis. TrAC Trends Anal Chem 2007, 26:486-493.
37. Price D.K., Ando Y., Kruger E.A., Weiss M., Figg W.D. 5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis. Ther Drug Monit 2002, 24:104-110.
38. Reist M., Carrupt P., Francotte E., Testa B. Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites. Chem Res Toxicol 1998, 11:1521-1528.
39. Rücker C., Kümmerer K. Modeling and predicting aquatic aerobic biodegradation - a review from a user's perspective. Green Chem 2012, 14:875.
40. Schumacher H., Smith R.L., Williams R.T. The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br J Pharmacol Chemother 1965, 25:338-351.
41. Schumacher H., Smith R.L., Williams R.T. The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br J Pharmacol Chemother 1965, 25:324-337.
42. Sedykh A., Saiakhov R., Klopman G.M.E.T.A.V. A model of photodegradation for the prediction of photoproducts of chemicals under natural-like conditions. Chemosphere 2001, 45:971-981.
43. Sweetman S.C. Martindale: the complete drug reference 2009, Pharmaceutical Press, London, Chicago. 36th ed.
44. Ternes T.A. Occurrence of drugs in German sewage treatment plants and rivers. Water Res 1998, 32:3245-3260.
45. Tixier C., Singer H.P., Oellers S., Müller S.R. Occurrence and fate of carbamazepine, clofibric acid, diclofenac, ibuprofen, ketoprofen, and naproxen in surface waters. Environ Sci Technol 2003, 37:1061-1068.
46. Tønnesen H.H. Photostability of drugs and drug formulations 2004, CRC Press, Boca Raton, New York. 2nd ed.
47. Trautwein C., Kümmerer K. Incomplete aerobic degradation of the antidiabetic drug metformin and identification of the bacterial dead-end transformation product guanylurea. Chemosphere 2011, 85:765-773.
48. n and QSAR. Environ Sci Pollut Res 2012, 19(8):3162-3177.
49. U.S.EPA United States Environmental Protection Agency, wastewater technology fact sheet ultraviolet disinfection [832-F99-064]. http://water.epa.gov/scitech/wastetech/upload/2002_06_28_mtb_uv.pdf.
50. U.S.National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894 THALIDOMIDE - National Library of Medicine HSDB database [accessed September 21, 2011]. http://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+3586.
51. US EPA United States Environmental Protection Agency EPA/OPPT/Exposure Assessment Tools and Models/Estimation Program Interface (EPI) suite version 3.12 (August 17, 2004) [accessed November 28, 2012]. http://www.epa.gov/oppt/exposure/pubs/episuite.htm.
52. Wolfbeis O.S. Fiber-optic chemical sensors and biosensors. Anal Chem 2002, 74:2663-2678.